

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Debra A. Wojcik  
Type or print name

Signature

4/19/04  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HAMANN ET AL.

APPLICATION NO: 10/712,456

FILED: NOVEMBER 13, 2003

FOR: OPEN CHAIN PROLYL UREA-RELATED MODULATORS OF  
ANDROGEN RECEPTOR FUNCTION

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-6270

  
\_\_\_\_\_  
Sammy G. Duncan Jr. Ph.D.  
Attorney for Applicants  
Reg. No. 46,675

Date: 4/19/04

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



Group

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,688,808	11/18/97	Jones et al.			
	AB	5,688,810	11/18/97	Jones et al.			
	AC	5,693,646	12/2/97	Jones et al.			
	AD	5,693,647	12/2/97	Jones et al.			
	AE	5,696,127	12/9/97	Jones et al.			
	AF	5,696,130	12/9/97	Jones et al.			
	AG	5,696,133	12/9/97	Jones et al.			
	AH						
	AI						
	AJ						
	AK						
	AL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	WO 96/19458	6/27/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 97/49709	12/31/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Banz, W.J. et al., "Effects of Soy Protein and Soy Phytoestrogens on Symptoms Associated with Cardiovascular Disease in Rats", Journal of Medicinal Food, Vol. 2, Nos. 3-4, pp. 271-273 (1999)
	AS	Bourguet, W. et al., "Crystal structure of the ligand-binding domain of the human nuclear receptor RXR- $\alpha$ ", Nature, Vol. 375, pp. 377-382 (1995)
	AT	Brzozowski, A.M. et al., "Molecular basis of agonism and antagonism in the oestrogen receptor", Nature, Vol. 389, pp. 753-758 (1997)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

LA0091 NP

APPLICATION NO.

10/712,456


APPLICANT

HAMANN ET AL.

FILING DATE

NOVEMBER 13, 2003

Group



## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Evans, R.M., "The Steroid and Thyroid Hormone Receptor Superfamily", Science, Vol. 240, pp. 889-895 (1988)
2AB	Grese, T.A. et al., "Molecular determinants of tissue selectivity in estrogen receptor modulators", Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 14105-14110 (1997)
2AC	Hamann, L.G. et al., "Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g]quinolines", J. Med. Chem., Vol. 41, No. 4, pp. 623-639 (1998)
2AD	Neri, R. et al., "A Biological Profile of a Nonsteroidal Antiandrogen, SCH 13521 (4'-Nitro-3'-Trifluoromethylisobutyranilide)", Endo, Vol. 91, No. 2, pp. 427-437 (1972)
2AE	Quella, S.K. et al., "Evaluation of Soy Phytoestrogens for the Treatment of Hot Flashes in Breast Cancer Survivors: A North Central Cancer Treatment Group Trial", Journal of Clinical Oncology, Vol. 18, No. 5, pp. 1068-1074 (2000)
2AF	Regal, J.F. et al., "Dietary Phytoestrogens Have Anti-Inflammatory Activity in a Guinea Pig Model of Asthma", Proc. Soc. Exp. Biol. Med., Vol. 223, pp. 372-378 (2000)
2AG	Shiau, A.K. et al., "The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen", Cell, Vol. 95, pp. 927-937 (1998)
2AH	Smigel, K., "Breast Cancer Prevention Trial Shows Major Benefit, Some Risk", Journal of the National Cancer Institute, Vol. 90, No. 9, pp. 647-648 (1998)
2AI	Tanenbaum, D.M. et al., "Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains", Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 5998-6003 (1998)
2AJ	Vegeto, E. et al., "The Mechanism of RU486 Antagonism Is Dependent on the Conformation of the Carboxy-Terminal Tail of the Human Progesterone Receptor", Cell, Vol. 69, pp. 703-713 (1992)
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.